# ELEVANCE HEALTH, INC. (ELV) FY2026 Q2 P&L / Income Statement

- Company: ELEVANCE HEALTH, INC. (ELV)
- Period: 2026-04-01 to 2026-06-30
- Filing: Q2 FY2026 10-Q, filed 2026-07-15, accession number 0001156039-26-000060
- Page: https://plicit.ai/financials/elv/fy2026-q2-income-statement
- Chart image: https://plicit.ai/charts/elv-fy2026-q2-income-statement-sankey.png

## Chart details: Revenue by Product and Service (3 categories)

Income statement for 2026-04-01 through 2026-06-30. View: Product and service (3 categories). Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Total revenues**: 50,474,000,000 US dollars
- **Total expenses**: 48,537,000,000 US dollars
- **Operating profit (calculated)**: 1,937,000,000 US dollars
- **Other income (expense), net (calculated)**: 0 US dollars
- **Income before income tax expense**: 1,937,000,000 US dollars
- **Income tax expense**: 483,000,000 US dollars
- **Net income**: 1,454,000,000 US dollars
- **Total operating revenue**: 49,826,000,000 US dollars
- **Net investment income**: 704,000,000 US dollars
- **Benefit expense**: 37,024,000,000 US dollars
- **Cost of products sold**: 5,492,000,000 US dollars
- **Operating expense**: 5,547,000,000 US dollars
- **Amortization of other intangible assets**: 110,000,000 US dollars
- **Interest expense**: 364,000,000 US dollars
- **Revenue before reconciliation (calculated)**: 50,530,000,000 US dollars. Sum of the reported revenue categories before the separately reported reconciliation.
- **Net losses on financial instruments**: negative 56,000,000 US dollars. Reported reconciliation to consolidated revenue.

### Chart connections

- Revenue minus operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
- Reported revenue categories plus the separately reported signed reconciliation equals consolidated revenue.
- Of which attributable to ELEVANCE HEALTH, INC.: $1.46 B; to noncontrolling interests: −$9.00 M.